Cabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer
Progression-free survival significantly longer with addition of cabozantinib in previously untreated advanced renal cell carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.